A prospective cohort study of patients with non-squamous non-small cell lung cancer treated with bevacizumab

  • Authors:
    • Katsuhiko Naoki
    • Yuichiro Takeda
    • Kenzo Soejima
    • Daisuke Arai
    • Go Naka
    • Seisuke Nagase
    • Ken Arimura
    • Toshinori Kanemura
    • Tatsuo Ohhira
    • Norihiko Ikeda
  • View Affiliations

  • Published online on: March 2, 2017     https://doi.org/10.3892/ol.2017.5796
  • Pages: 3285-3290
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

First-line chemotherapy regimens that include bevacizumab (Bev) have been hypothesized to improve outcomes in patients with advanced non-squamous non‑small cell lung cancer (non‑sq NSCLC). Although approved to treat NSCLC in 2009, insufficient data exist on the clinical uses of Bev in Japan. The present study prospectively evaluated the efficacy and safety of Bev-containing combination chemotherapy. Eligible patients exhibited histologically or cytologically documented advanced or recurrent non‑sq NSCLC. Patients were administered 15 mg/kg Bev with standard chemotherapy followed by maintenance Bev. The primary endpoints were progression‑free survival (PFS) and safety. A total of 102 patients with non‑sq NSCLC were enrolled, 44.1% of whose tumor carried epidermal growth factor receptor (EGFR) mutations. The overall response rate to the intervention was 44.1%, and the median PFS was 8.3 months [95% confidence interval (CI)=6.4‑10.2 months]. The median overall survival was 26.3 months (95% CI=22.2‑30.4 months). The incidence of Bev‑associated severe adverse events was similar to those in previous trials, excluding a grade 3‑4 hypertension rate of 30.4% in the present study. Multivariate analysis revealed that a higher TNM classification of malignant tumor staging‑T factor, adjusted hazard ratio (HR)=1.33 (95% CI=1.10‑1.61), and poor performance status [adjusted HR=1.63 (1.02‑2.60)] were associated with significantly shorter PFS, whilst the EGFR exon 19 deletion was significantly associated with prolonged PFS [adjusted HR=0.47 (0.25‑0.87)]. Bev‑containing chemotherapy was safe and effective for patients with non‑sq NSCLC in clinical settings in Japan. The EGFR exon 19 deletion was suggested as a positive predictive factor for the efficacy of Bev‑containing chemotherapy.
View Figures
View References

Related Articles

Journal Cover

May-2017
Volume 13 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Naoki K, Takeda Y, Soejima K, Arai D, Naka G, Nagase S, Arimura K, Kanemura T, Ohhira T, Ikeda N, Ikeda N, et al: A prospective cohort study of patients with non-squamous non-small cell lung cancer treated with bevacizumab. Oncol Lett 13: 3285-3290, 2017
APA
Naoki, K., Takeda, Y., Soejima, K., Arai, D., Naka, G., Nagase, S. ... Ikeda, N. (2017). A prospective cohort study of patients with non-squamous non-small cell lung cancer treated with bevacizumab. Oncology Letters, 13, 3285-3290. https://doi.org/10.3892/ol.2017.5796
MLA
Naoki, K., Takeda, Y., Soejima, K., Arai, D., Naka, G., Nagase, S., Arimura, K., Kanemura, T., Ohhira, T., Ikeda, N."A prospective cohort study of patients with non-squamous non-small cell lung cancer treated with bevacizumab". Oncology Letters 13.5 (2017): 3285-3290.
Chicago
Naoki, K., Takeda, Y., Soejima, K., Arai, D., Naka, G., Nagase, S., Arimura, K., Kanemura, T., Ohhira, T., Ikeda, N."A prospective cohort study of patients with non-squamous non-small cell lung cancer treated with bevacizumab". Oncology Letters 13, no. 5 (2017): 3285-3290. https://doi.org/10.3892/ol.2017.5796